drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00060 | DB00398 | 912 | 79 | [
"DDInter947",
"DDInter1702"
] | Interferon beta-1a | Sorafenib | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
912,
24,
79
]
],
[
[
912,
24,
292
],
[
292,
40,
79
]
],
[
[
912,
24,
1247
],
[
1247,
62,
79
]
],
[
[
912,
24,
126
],
[
126,
63,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib (Compound) resembles Sorafenib (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a mi... |
DB01191 | DB08896 | 1,039 | 292 | [
"DDInter518",
"DDInter1576"
] | Dexfenfluramine | Regorafenib | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
1039,
24,
292
]
],
[
[
1039,
6,
6017
],
[
6017,
45,
292
]
],
[
[
1039,
24,
549
],
[
549,
23,
292
]
],
[
[
1039,
25,
643
],
[
643,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Dexfenfluramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (... | Dexfenfluramine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
De... |
DB01087 | DB08864 | 1,520 | 786 | [
"DDInter1520",
"DDInter1595"
] | Primaquine | Rilpivirine | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
1520,
24,
786
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
786
]
],
[
[
1520,
21,
28722
],
[
28722,
60,
786
]
],
[
[
1520,
62,
112
],
[
112,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Primaquine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Rilpivirine (Compound)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metroni... |
DB05528 | DB08916 | 1,070 | 26 | [
"DDInter1228",
"DDInter32"
] | Mipomersen | Afatinib | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Major | 2 | [
[
[
1070,
25,
26
]
],
[
[
1070,
64,
883
],
[
883,
40,
26
]
],
[
[
1070,
25,
1320
],
[
1320,
63,
26
]
],
[
[
1070,
64,
79
],
[
79,
24... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Afatinib"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Comp... | Mipomersen may lead to a major life threatening interaction when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Mipomersen may lead to a major life threatening interaction when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with A... |
DB00026 | DB01206 | 1,184 | 37 | [
"DDInter94",
"DDInter1086"
] | Anakinra | Lomustine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1184,
24,
37
]
],
[
[
1184,
24,
697
],
[
697,
23,
37
]
],
[
[
1184,
24,
141
],
[
141,
24,
37
]
],
[
[
1184,
24,
259
],
[
259,
63... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lomustine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxur... |
DB00497 | DB11730 | 828 | 351 | [
"DDInter1366",
"DDInter1588"
] | Oxycodone | Ribociclib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
828,
25,
351
]
],
[
[
828,
24,
222
],
[
222,
23,
351
]
],
[
[
828,
25,
283
],
[
283,
62,
351
]
],
[
[
828,
64,
597
],
[
597,
24,... | [
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Oxycodone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a ... |
DB00992 | DB12455 | 842 | 933 | [
"DDInter1182",
"DDInter1336"
] | Methyl aminolevulinate (topical) | Omadacycline | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in ani... | Moderate | 1 | [
[
[
842,
24,
933
]
],
[
[
842,
75,
213
],
[
213,
25,
933
]
],
[
[
842,
21,
29196
],
[
29196,
60,
803
],
[
803,
24,
933
]
],
[
[
842,
... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Methyl aminolevulinate",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction w... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Methyl aminolevulinate (Compound) resembles Aminolevulinic acid (Compound) and Methyl aminolevulinate may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulini... |
DB00370 | DB09080 | 1,251 | 144 | [
"DDInter1230",
"DDInter1331"
] | Mirtazapine | Olodaterol | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1251,
24,
144
]
],
[
[
1251,
25,
11
],
[
11,
24,
144
]
],
[
[
1251,
24,
543
],
[
543,
24,
144
]
],
[
[
1251,
63,
1324
],
[
1324,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremife... | Mirtazapine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may caus... |
DB06772 | DB09280 | 310 | 1,604 | [
"DDInter259",
"DDInter1101"
] | Cabazitaxel | Lumacaftor | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
310,
24,
1604
]
],
[
[
310,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
310,
63,
671
],
[
671,
24,
1604
]
],
[
[
310,
24,
1468
],
[
1468,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fluva... |
DB08879 | DB09322 | 632 | 1,114 | [
"DDInter173",
"DDInter1966"
] | Belimumab | Zinc sulfate | Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A2... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
632,
23,
1114
]
],
[
[
632,
63,
66
],
[
66,
23,
1114
]
],
[
[
632,
64,
1057
],
[
1057,
23,
1114
]
],
[
[
632,
24,
270
],
[
270,
... | [
[
[
"Belimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Belimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Belimumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Belimumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a ... |
DB00951 | DB06723 | 1,072 | 115 | [
"DDInter986",
"DDInter58"
] | Isoniazid | Aluminum hydroxide | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
1072,
23,
115
]
],
[
[
1072,
21,
28882
],
[
28882,
60,
115
]
],
[
[
1072,
62,
870
],
[
870,
23,
115
]
],
[
[
1072,
23,
1486
],
[
1486,... | [
[
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Isoniazid",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increa... | Isoniazid (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Aluminum hydroxide (Compound)
Isoniazid may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can ... |
DB04908 | DB12141 | 1,671 | 971 | [
"DDInter741",
"DDInter817"
] | Flibanserin | Gilteritinib | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1671,
24,
971
]
],
[
[
1671,
23,
1135
],
[
1135,
23,
971
]
],
[
[
1671,
63,
820
],
[
820,
24,
971
]
],
[
[
1671,
24,
1409
],
[
1409,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Flibanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Flibanserin may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimema... |
DB00515 | DB00831 | 589 | 1,178 | [
"DDInter387",
"DDInter1866"
] | Cisplatin | Trifluoperazine | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
589,
24,
1178
]
],
[
[
589,
64,
695
],
[
695,
40,
1178
]
],
[
[
589,
63,
216
],
[
216,
40,
1178
]
],
[
[
589,
24,
684
],
[
684,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapin... | Cisplatin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Trifluoperazine (Compound)
C... |
DB00365 | DB00581 | 839 | 355 | [
"DDInter842",
"DDInter1018"
] | Grepafloxacin | Lactulose | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
839,
24,
355
]
],
[
[
839,
63,
1647
],
[
1647,
1,
355
]
],
[
[
839,
24,
1475
],
[
1475,
62,
355
]
],
[
[
839,
25,
79
],
[
79,
24... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose (Compound) resembles Lactulose (Compound)
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a minor interaction that... |
DB00358 | DB01591 | 1,010 | 667 | [
"DDInter1140",
"DDInter1696"
] | Mefloquine | Solifenacin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1010,
24,
667
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
667
]
],
[
[
1010,
21,
28723
],
[
28723,
60,
667
]
],
[
[
1010,
23,
112
],
[
112,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Mefloquine (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Solifenacin (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB00398 | DB00480 | 79 | 1,668 | [
"DDInter1702",
"DDInter1035"
] | Sorafenib | Lenalidomide | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Moderate | 1 | [
[
[
79,
24,
1668
]
],
[
[
79,
24,
770
],
[
770,
40,
1668
]
],
[
[
79,
6,
4973
],
[
4973,
45,
1668
]
],
[
[
79,
7,
4450
],
[
4450,
46... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound)
Sorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lenalidomide (Compound)
Sorafenib (Compound) upregulates RRP8 (Gene) and RRP8 (Gene) is ... |
DB01058 | DB09420 | 978 | 1,074 | [
"DDInter1510",
"DDInter953"
] | Praziquantel | Iodide I-123 | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
978,
24,
1074
]
],
[
[
978,
62,
510
],
[
510,
24,
1074
]
],
[
[
978,
24,
1220
],
[
1220,
24,
1074
]
],
[
[
978,
63,
1249
],
[
1249,
... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Praziquantel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albendazole"
],
... | Praziquantel may cause a minor interaction that can limit clinical effects when taken with Albendazole and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone a... |
DB06589 | DB11817 | 1,250 | 1,259 | [
"DDInter1400",
"DDInter165"
] | Pazopanib | Baricitinib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1250,
25,
1259
]
],
[
[
1250,
24,
949
],
[
949,
24,
1259
]
],
[
[
1250,
63,
563
],
[
563,
24,
1259
]
],
[
[
1250,
64,
828
],
[
828,
... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formalde... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Pazopanib ma... |
DB00332 | DB04843 | 1,089 | 1,511 | [
"DDInter970",
"DDInter1149"
] | Ipratropium | Mepenzolate | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1089,
24,
1511
]
],
[
[
1089,
24,
537
],
[
537,
24,
1511
]
],
[
[
1089,
63,
352
],
[
352,
24,
1511
]
],
[
[
1089,
24,
1429
],
[
1429,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospiu... |
DB00865 | DB09104 | 939 | 286 | [
"DDInter187",
"DDInter1118"
] | Benzphetamine | Magnesium hydroxide | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
939,
24,
286
]
],
[
[
939,
24,
820
],
[
820,
23,
286
]
],
[
[
939,
63,
999
],
[
999,
23,
286
]
],
[
[
939,
24,
688
],
[
688,
24,... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Thieth... |
DB00987 | DB09074 | 1,224 | 1,362 | [
"DDInter460",
"DDInter1327"
] | Cytarabine | Olaparib | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1224,
24,
1362
]
],
[
[
1224,
63,
896
],
[
896,
24,
1362
]
],
[
[
1224,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
1224,
24,
385
],
[
385,
... | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinum... |
DB01044 | DB09078 | 246 | 1,228 | [
"DDInter809",
"DDInter1036"
] | Gatifloxacin | Lenvatinib | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
246,
25,
1228
]
],
[
[
246,
62,
112
],
[
112,
23,
1228
]
],
[
[
246,
25,
609
],
[
609,
24,
1228
]
],
[
[
246,
63,
770
],
[
770,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Gatifloxacin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromy... |
DB04868 | DB08827 | 478 | 990 | [
"DDInter1293",
"DDInter1085"
] | Nilotinib | Lomitapide | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
478,
25,
990
]
],
[
[
478,
64,
1080
],
[
1080,
1,
990
]
],
[
[
478,
6,
8374
],
[
8374,
45,
990
]
],
[
[
478,
21,
28701
],
[
28701,
... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} (Co... | Nilotinib may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Nilotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Nilotinib (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) i... |
DB00041 | DB01589 | 1,648 | 481 | [
"DDInter38",
"DDInter1552"
] | Aldesleukin | Quazepam | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
1648,
24,
481
]
],
[
[
1648,
24,
1216
],
[
1216,
1,
481
]
],
[
[
1648,
24,
905
],
[
905,
40,
481
]
],
[
[
1648,
24,
1532
],
[
1532,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound)
Alde... |
DB01136 | DB11363 | 772 | 1,276 | [
"DDInter305",
"DDInter39"
] | Carvedilol | Alectinib | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
772,
24,
1276
]
],
[
[
772,
25,
1011
],
[
1011,
24,
1276
]
],
[
[
772,
63,
1528
],
[
1528,
24,
1276
]
],
[
[
772,
24,
1476
],
[
1476,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Carvedilol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod"... | Carvedilol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may c... |
DB00414 | DB13873 | 590 | 1,534 | [
"DDInter16",
"DDInter719"
] | Acetohexamide | Fenofibric acid | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Moderate | 1 | [
[
[
590,
24,
1534
]
],
[
[
590,
63,
176
],
[
176,
24,
1534
]
],
[
[
590,
24,
1144
],
[
1144,
24,
1534
]
],
[
[
590,
24,
1377
],
[
1377,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01601 | DB11057 | 833 | 720 | [
"DDInter1089",
"DDInter1223"
] | Lopinavir | Mineral oil | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to ... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
833,
24,
720
]
],
[
[
833,
25,
1069
],
[
1069,
24,
720
]
],
[
[
833,
24,
1616
],
[
1616,
24,
720
]
],
[
[
833,
63,
79
],
[
79,
2... | [
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib"... | Lopinavir may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a m... |
DB00196 | DB01124 | 600 | 1,411 | [
"DDInter743",
"DDInter1828"
] | Fluconazole | Tolbutamide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Major | 2 | [
[
[
600,
25,
1411
]
],
[
[
600,
25,
959
],
[
959,
40,
1411
]
],
[
[
600,
6,
10215
],
[
10215,
45,
1411
]
],
[
[
600,
21,
29455
],
[
29455,... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} ... | Fluconazole may lead to a major life threatening interaction when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Fluconazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Fluconazole (Compound) causes Agranulocytosis (Side Effect) and Agranulocytos... |
DB00502 | DB00857 | 1,300 | 1,387 | [
"DDInter853",
"DDInter1768"
] | Haloperidol | Terbinafine | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
1300,
24,
1387
]
],
[
[
1300,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
1300,
18,
2183
],
[
2183,
57,
1387
]
],
[
[
1300,
21,
29047
],
[
29... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Haloperidol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Haloperidol (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Terbinafine (Compound)
Haloperidol (Compound) causes Hepatic function abnormal (Side Effect) and Hepatic function abnormal (Side Effect) ... |
DB00795 | DB01276 | 50 | 123 | [
"DDInter1725",
"DDInter706"
] | Sulfasalazine | Exenatide | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
50,
24,
123
]
],
[
[
50,
63,
1252
],
[
1252,
23,
123
]
],
[
[
50,
24,
1476
],
[
1476,
63,
123
]
],
[
[
50,
24,
1338
],
[
1338,
2... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatini... |
DB00061 | DB12839 | 403 | 919 | [
"DDInter1402",
"DDInter1411"
] | Pegademase | Pegvaliase | Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life. | Pegvaliase is a recombinant phenylalanine ammonia lyase (PAL) enzyme derived from _Anabaena variabilis_ that converts phenylalanine to ammonia and _trans_-cinnamic acid . Both the U.S. Food and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients wit... | Moderate | 1 | [
[
[
403,
24,
919
]
],
[
[
403,
24,
934
],
[
934,
24,
919
]
],
[
[
403,
24,
934
],
[
934,
63,
1257
],
[
1257,
24,
919
]
]
] | [
[
[
"Pegademase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegvaliase"
]
],
[
[
"Pegademase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegloticase"
],
[
... | Pegademase may cause a moderate interaction that could exacerbate diseases when taken with Pegloticase and Pegloticase may cause a moderate interaction that could exacerbate diseases when taken with Pegvaliase
Pegademase may cause a moderate interaction that could exacerbate diseases when taken with Pegloticase and Peg... |
DB01234 | DB13139 | 1,220 | 1,032 | [
"DDInter513",
"DDInter1063"
] | Dexamethasone | Levosalbutamol | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Minor | 0 | [
[
[
1220,
23,
1032
]
],
[
[
1220,
40,
218
],
[
218,
23,
1032
]
],
[
[
1220,
1,
1486
],
[
1486,
23,
1032
]
],
[
[
1220,
24,
1618
],
[
1618,... | [
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Beclomethasone dipropionate"
],
[
"Beclomethasone dip... | Dexamethasone (Compound) resembles Beclomethasone dipropionate (Compound) and Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Dexamethasone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a minor interaction tha... |
DB00675 | DB01263 | 888 | 859 | [
"DDInter1744",
"DDInter1494"
] | Tamoxifen | Posaconazole | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
888,
24,
859
]
],
[
[
888,
6,
4973
],
[
4973,
45,
859
]
],
[
[
888,
21,
28762
],
[
28762,
60,
859
]
],
[
[
888,
23,
112
],
[
112,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Tamoxifen (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Tamoxifen (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metron... |
DB00041 | DB00457 | 1,648 | 1,205 | [
"DDInter38",
"DDInter1511"
] | Aldesleukin | Prazosin | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTS... | Moderate | 1 | [
[
[
1648,
24,
1205
]
],
[
[
1648,
24,
195
],
[
195,
1,
1205
]
],
[
[
1648,
24,
999
],
[
999,
24,
1205
]
],
[
[
1648,
24,
714
],
[
714,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prazosin"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Terazosin and Terazosin (Compound) resembles Prazosin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction ... |
DB11979 | DB12141 | 1,320 | 971 | [
"DDInter625",
"DDInter817"
] | Elagolix | Gilteritinib | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1320,
24,
971
]
],
[
[
1320,
63,
1135
],
[
1135,
23,
971
]
],
[
[
1320,
24,
466
],
[
466,
62,
971
]
],
[
[
1320,
63,
1335
],
[
1335,
... | [
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutami... |
DB01611 | DB06792 | 1,487 | 1,606 | [
"DDInter893",
"DDInter1023"
] | Hydroxychloroquine | Lanthanum carbonate | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
1487,
24,
1606
]
],
[
[
1487,
62,
88
],
[
88,
24,
1606
]
],
[
[
1487,
63,
556
],
[
556,
24,
1606
]
],
[
[
1487,
64,
945
],
[
945,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Meto... | Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00553 | DB15233 | 92 | 1,650 | [
"DDInter1177",
"DDInter142"
] | Methoxsalen | Avapritinib | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
92,
24,
1650
]
],
[
[
92,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
92,
24,
918
],
[
918,
24,
1650
]
],
[
[
92,
24,
848
],
[
848,
25... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[... | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and B... |
DB00748 | DB00777 | 662 | 146 | [
"DDInter297",
"DDInter1537"
] | Carbinoxamine | Propiomazine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
662,
24,
146
]
],
[
[
662,
63,
508
],
[
508,
1,
146
]
],
[
[
662,
24,
401
],
[
401,
63,
146
]
],
[
[
662,
24,
1178
],
[
1178,
1,... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction ... |
DB00446 | DB09050 | 597 | 931 | [
"DDInter351",
"DDInter333"
] | Chloramphenicol | Ceftolozane | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmac... | Moderate | 1 | [
[
[
597,
24,
931
]
],
[
[
597,
24,
1096
],
[
1096,
24,
931
]
],
[
[
597,
24,
1096
],
[
1096,
63,
361
],
[
361,
24,
931
]
],
[
[
597,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftolozane"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic aci... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Ceftolozane
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00975 | DB06779 | 1,317 | 365 | [
"DDInter573",
"DDInter470"
] | Dipyridamole | Dalteparin | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
1317,
25,
365
]
],
[
[
1317,
23,
539
],
[
539,
62,
365
]
],
[
[
1317,
63,
305
],
[
305,
24,
365
]
],
[
[
1317,
24,
1496
],
[
1496,
... | [
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Dipyridamole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",... | Dipyridamole may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia ... |
DB01172 | DB14761 | 416 | 242 | [
"DDInter1004",
"DDInter1578"
] | Kanamycin | Remdesivir | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
416,
24,
242
]
],
[
[
416,
63,
1512
],
[
1512,
24,
242
]
],
[
[
416,
74,
361
],
[
361,
24,
242
]
],
[
[
416,
40,
1647
],
[
1647,
... | [
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
... | Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Kanamycin (Compound) resembles Neomycin (Compound) and Kanamycin may cause a moderate interaction that could exac... |
DB09564 | DB12015 | 1,296 | 1,033 | [
"DDInter930",
"DDInter53"
] | Insulin degludec | Alpelisib | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1296,
24,
1033
]
],
[
[
1296,
63,
154
],
[
154,
24,
1033
]
],
[
[
1296,
24,
1385
],
[
1385,
63,
1033
]
],
[
[
1296,
24,
433
],
[
433,
... | [
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
... | Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Semaglutid... |
DB08895 | DB09098 | 976 | 98 | [
"DDInter1825",
"DDInter1700"
] | Tofacitinib | Somatrem | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
976,
24,
98
]
],
[
[
976,
63,
608
],
[
608,
23,
98
]
],
[
[
976,
64,
168
],
[
168,
23,
98
]
],
[
[
976,
24,
159
],
[
159,
63,
... | [
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Tofacitinib may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a mi... |
DB00196 | DB00277 | 600 | 1,031 | [
"DDInter743",
"DDInter1791"
] | Fluconazole | Theophylline | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
600,
24,
1031
]
],
[
[
600,
6,
6017
],
[
6017,
45,
1031
]
],
[
[
600,
21,
28666
],
[
28666,
60,
1031
]
],
[
[
600,
25,
523
],
[
523,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compoun... | Fluconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Theophylline (Compound)
Fluconazole (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Theophylline (Compound)
Fluconazole may lead to a major life threatening interaction when taken with... |
DB00374 | DB00580 | 1,061 | 311 | [
"DDInter1852",
"DDInter1910"
] | Treprostinil | Valdecoxib | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Moderate | 1 | [
[
[
1061,
24,
311
]
],
[
[
1061,
63,
366
],
[
366,
24,
311
]
],
[
[
1061,
25,
500
],
[
500,
63,
311
]
],
[
[
1061,
24,
936
],
[
936,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eptifibatide"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Treprostinil may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin ma... |
DB00861 | DB01124 | 914 | 1,411 | [
"DDInter551",
"DDInter1828"
] | Diflunisal | Tolbutamide | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
914,
24,
1411
]
],
[
[
914,
24,
959
],
[
959,
40,
1411
]
],
[
[
914,
63,
245
],
[
245,
40,
1411
]
],
[
[
914,
6,
10612
],
[
10612,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB00009 | DB11793 | 1,271 | 738 | [
"DDInter56",
"DDInter1297"
] | Alteplase | Niraparib | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1271,
24,
738
]
],
[
[
1271,
25,
1213
],
[
1213,
24,
738
]
],
[
[
1271,
64,
1578
],
[
1578,
24,
738
]
],
[
[
1271,
24,
848
],
[
848,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Alteplase may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction... |
DB09389 | DB11767 | 517 | 1,583 | [
"DDInter1315",
"DDInter1643"
] | Norgestrel | Sarilumab | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
517,
24,
1583
]
],
[
[
517,
63,
1362
],
[
1362,
24,
1583
]
],
[
[
517,
63,
1064
],
[
1064,
25,
1583
]
],
[
[
517,
63,
1362
],
[
1362,
... | [
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine ... |
DB01261 | DB14509 | 170 | 1,399 | [
"DDInter1679",
"DDInter1081"
] | Sitagliptin | Lithium carbonate | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
170,
24,
1399
]
],
[
[
170,
63,
874
],
[
874,
23,
1399
]
],
[
[
170,
63,
820
],
[
820,
24,
1399
]
],
[
[
170,
24,
927
],
[
927,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine ... |
DB06616 | DB09122 | 594 | 1,613 | [
"DDInter224",
"DDInter1409"
] | Bosutinib | Peginterferon beta-1a | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
594,
24,
1613
]
],
[
[
594,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
594,
64,
152
],
[
152,
24,
1613
]
],
[
[
594,
25,
1155
],
[
1155,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bosutinib may lead to a major life threatening interaction when taken with Bosentan and Bosentan may... |
DB00005 | DB00593 | 1,057 | 1,464 | [
"DDInter687",
"DDInter695"
] | Etanercept | Ethosuximide | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Moderate | 1 | [
[
[
1057,
24,
1464
]
],
[
[
1057,
25,
1184
],
[
1184,
24,
1464
]
],
[
[
1057,
25,
1303
],
[
1303,
63,
1464
]
],
[
[
1057,
24,
1487
],
[
14... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",... | Etanercept may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Etanercept may lead to a major life threatening interaction when taken with Guselkumab and Guselkumab may cause a moderate intera... |
DB00004 | DB11793 | 669 | 738 | [
"DDInter499",
"DDInter1297"
] | Denileukin diftitox | Niraparib | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
669,
24,
738
]
],
[
[
669,
24,
496
],
[
496,
24,
738
]
],
[
[
669,
25,
770
],
[
770,
24,
738
]
],
[
[
669,
24,
1129
],
[
1129,
6... | [
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis ... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Denileukin diftitox may lead to a major life threatening interaction when taken with T... |
DB00564 | DB05679 | 1,236 | 1,683 | [
"DDInter293",
"DDInter1907"
] | Carbamazepine | Ustekinumab | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1236,
24,
1683
]
],
[
[
1236,
24,
1042
],
[
1042,
24,
1683
]
],
[
[
1236,
25,
1362
],
[
1362,
63,
1683
]
],
[
[
1236,
24,
1093
],
[
10... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carbamazepine may lead to a major life threatening interaction when taken with Olaparib and Olaparib... |
DB01069 | DB11718 | 401 | 927 | [
"DDInter1533",
"DDInter640"
] | Promethazine | Encorafenib | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
401,
24,
927
]
],
[
[
401,
62,
112
],
[
112,
23,
927
]
],
[
[
401,
74,
216
],
[
216,
24,
927
]
],
[
[
401,
24,
659
],
[
659,
24,... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Promethazine (Compound) resembles Chlorpromazine (Compound) and Promethazine may cause a moderate interacti... |
DB06414 | DB11837 | 655 | 1,297 | [
"DDInter703",
"DDInter1351"
] | Etravirine | Osilodrostat | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
655,
24,
1297
]
],
[
[
655,
24,
1135
],
[
1135,
23,
1297
]
],
[
[
655,
63,
112
],
[
112,
23,
1297
]
],
[
[
655,
24,
466
],
[
466,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metro... |
DB01073 | DB06643 | 1,488 | 1,136 | [
"DDInter745",
"DDInter500"
] | Fludarabine | Denosumab | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1488,
24,
1136
]
],
[
[
1488,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
1488,
24,
1532
],
[
1532,
24,
1136
]
],
[
[
1488,
24,
1480
],
[
14... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifo... |
DB01039 | DB01309 | 535 | 1,254 | [
"DDInter718",
"DDInter933"
] | Fenofibrate | Insulin glulisine | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
535,
24,
1254
]
],
[
[
535,
63,
305
],
[
305,
24,
1254
]
],
[
[
535,
24,
850
],
[
850,
63,
1254
]
],
[
[
535,
24,
1411
],
[
1411,
... | [
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Esche... | Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Fenofibrate may cause a moderate interaction that could exacerbate... |
DB00372 | DB00748 | 999 | 662 | [
"DDInter1793",
"DDInter297"
] | Thiethylperazine | Carbinoxamine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
999,
24,
662
]
],
[
[
999,
63,
1594
],
[
1594,
24,
662
]
],
[
[
999,
24,
128
],
[
128,
24,
662
]
],
[
[
999,
24,
1429
],
[
1429,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbro... |
DB01009 | DB11703 | 935 | 405 | [
"DDInter1009",
"DDInter9"
] | Ketoprofen | Acalabrutinib | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
935,
25,
405
]
],
[
[
935,
62,
1194
],
[
1194,
24,
405
]
],
[
[
935,
63,
121
],
[
121,
24,
405
]
],
[
[
935,
24,
1017
],
[
1017,
... | [
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ketoprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidin... | Ketoprofen may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fen... |
DB00222 | DB00226 | 245 | 1,000 | [
"DDInter825",
"DDInter845"
] | Glimepiride | Guanadrel | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Moderate | 1 | [
[
[
245,
24,
1000
]
],
[
[
245,
24,
22
],
[
22,
63,
1000
]
],
[
[
245,
40,
959
],
[
959,
63,
1000
]
],
[
[
245,
63,
73
],
[
73,
24,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanadrel"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could ex... |
DB00361 | DB10276 | 134 | 1,624 | [
"DDInter1939",
"DDInter1623"
] | Vinorelbine | Rotavirus vaccine | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
134,
25,
1624
]
],
[
[
134,
63,
552
],
[
552,
25,
1624
]
],
[
[
134,
24,
1307
],
[
1307,
25,
1624
]
],
[
[
134,
25,
770
],
[
770,
... | [
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"C... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may... |
DB00960 | DB09333 | 887 | 278 | [
"DDInter1471",
"DDInter963"
] | Pindolol | Iopodic acid | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
887,
24,
278
]
],
[
[
887,
63,
1648
],
[
1648,
24,
278
]
],
[
[
887,
24,
1527
],
[
1527,
24,
278
]
],
[
[
887,
40,
726
],
[
726,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and I... |
DB00754 | DB01611 | 157 | 1,487 | [
"DDInter696",
"DDInter893"
] | Ethotoin | Hydroxychloroquine | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
157,
24,
1487
]
],
[
[
157,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
157,
63,
663
],
[
663,
23,
1487
]
],
[
[
157,
63,
597
],
[
597,
... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Ethotoin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is ca... | Ethotoin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Hyd... |
DB00302 | DB00717 | 335 | 1,197 | [
"DDInter1844",
"DDInter1312"
] | Tranexamic acid | Norethisterone | Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. It was first patented in 1957 and received its initial US approval in 1986. | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Major | 2 | [
[
[
335,
25,
1197
]
],
[
[
335,
25,
35
],
[
35,
40,
1197
]
],
[
[
335,
64,
1336
],
[
1336,
40,
1197
]
],
[
[
335,
21,
28751
],
[
28751,
... | [
[
[
"Tranexamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norethisterone"
]
],
[
[
"Tranexamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinestrol"
],
[
"Quinestrol"... | Tranexamic acid may lead to a major life threatening interaction when taken with Quinestrol and Quinestrol (Compound) resembles Norethisterone (Compound)
Tranexamic acid may lead to a major life threatening interaction when taken with Etonogestrel and Etonogestrel (Compound) resembles Norethisterone (Compound)
Tranexam... |
DB06663 | DB14723 | 1,154 | 159 | [
"DDInter1398",
"DDInter1026"
] | Pasireotide | Larotrectinib | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1154,
24,
159
]
],
[
[
1154,
23,
907
],
[
907,
23,
159
]
],
[
[
1154,
63,
479
],
[
479,
23,
159
]
],
[
[
1154,
64,
318
],
[
318,
... | [
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pasireotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[... | Pasireotide may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepe... |
DB00612 | DB01246 | 1,121 | 820 | [
"DDInter216",
"DDInter45"
] | Bisoprolol | Alimemazine | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1121,
24,
820
]
],
[
[
1121,
24,
104
],
[
104,
40,
820
]
],
[
[
1121,
24,
401
],
[
401,
24,
820
]
],
[
[
1121,
6,
8374
],
[
8374,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction t... |
DB00341 | DB11859 | 1,242 | 418 | [
"DDInter343",
"DDInter230"
] | Cetirizine | Brexanolone | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
1242,
24,
418
]
],
[
[
1242,
24,
820
],
[
820,
24,
418
]
],
[
[
1242,
63,
1648
],
[
1648,
24,
418
]
],
[
[
1242,
74,
701
],
[
701,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Al... |
DB00106 | DB00370 | 618 | 1,251 | [
"DDInter4",
"DDInter1230"
] | Abarelix | Mirtazapine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Moderate | 1 | [
[
[
618,
24,
1251
]
],
[
[
618,
23,
112
],
[
112,
62,
1251
]
],
[
[
618,
24,
392
],
[
392,
63,
1251
]
],
[
[
618,
24,
1010
],
[
1010,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mirtazapine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatini... |
DB06605 | DB08901 | 1,409 | 1,468 | [
"DDInter108",
"DDInter1492"
] | Apixaban | Ponatinib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1409,
25,
1468
]
],
[
[
1409,
63,
478
],
[
478,
24,
1468
]
],
[
[
1409,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
1409,
21,
28883
],
[
2888... | [
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Apixaban (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Apixaban (Compound) causes... |
DB00285 | DB12245 | 1,100 | 823 | [
"DDInter1927",
"DDInter1863"
] | Venlafaxine | Triclabendazole | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
1100,
24,
823
]
],
[
[
1100,
23,
112
],
[
112,
23,
823
]
],
[
[
1100,
24,
1010
],
[
1010,
24,
823
]
],
[
[
1100,
25,
1494
],
[
1494,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Venlafaxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine a... |
DB01050 | DB04861 | 848 | 1,592 | [
"DDInter900",
"DDInter1271"
] | Ibuprofen | Nebivolol | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
848,
24,
1592
]
],
[
[
848,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
848,
64,
1479
],
[
1479,
23,
1592
]
],
[
[
848,
24,
578
],
[
578,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Ibuprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by... | Ibuprofen (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Ibuprofen may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Nebivolol... |
DB01105 | DB04908 | 222 | 1,671 | [
"DDInter1665",
"DDInter741"
] | Sibutramine | Flibanserin | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
222,
24,
1671
]
],
[
[
222,
24,
98
],
[
98,
63,
1671
]
],
[
[
222,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
222,
24,
537
],
[
537,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylam... |
DB09104 | DB14881 | 286 | 180 | [
"DDInter1118",
"DDInter1329"
] | Magnesium hydroxide | Oliceridine | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
286,
24,
180
]
],
[
[
286,
62,
401
],
[
401,
24,
180
]
],
[
[
286,
24,
124
],
[
124,
24,
180
]
],
[
[
286,
63,
618
],
[
618,
24,... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promethazi... | Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB09039 | DB09046 | 1,670 | 1,094 | [
"DDInter629",
"DDInter1201"
] | Eliglustat | Metreleptin | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
1670,
24,
1094
]
],
[
[
1670,
25,
230
],
[
230,
62,
1094
]
],
[
[
1670,
23,
1135
],
[
1135,
63,
1094
]
],
[
[
1670,
63,
866
],
[
866,
... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
],
[
"Relugolix"... | Eliglustat may lead to a major life threatening interaction when taken with Relugolix and Relugolix may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moder... |
DB08901 | DB11817 | 1,468 | 1,259 | [
"DDInter1492",
"DDInter165"
] | Ponatinib | Baricitinib | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1468,
25,
1259
]
],
[
[
1468,
76,
1274
],
[
1274,
24,
1259
]
],
[
[
1468,
64,
598
],
[
598,
24,
1259
]
],
[
[
1468,
24,
949
],
[
949,
... | [
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interac... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ponatinib may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Ponatinib may le... |
DB00377 | DB01044 | 1,494 | 246 | [
"DDInter1382",
"DDInter809"
] | Palonosetron | Gatifloxacin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Major | 2 | [
[
[
1494,
25,
246
]
],
[
[
1494,
24,
739
],
[
739,
1,
246
]
],
[
[
1494,
64,
1176
],
[
1176,
1,
246
]
],
[
[
1494,
25,
945
],
[
945,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lo... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)... |
DB00081 | DB06688 | 273 | 1,430 | [
"DDInter1838",
"DDInter1677"
] | Tositumomab | Sipuleucel-T | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
273,
24,
1430
]
],
[
[
273,
24,
869
],
[
869,
24,
1430
]
],
[
[
273,
25,
676
],
[
676,
63,
1430
]
],
[
[
273,
24,
713
],
[
713,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Tositumomab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may ... |
DB01268 | DB12500 | 1,151 | 283 | [
"DDInter1731",
"DDInter714"
] | Sunitinib | Fedratinib | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1151,
24,
283
]
],
[
[
1151,
25,
351
],
[
351,
23,
283
]
],
[
[
1151,
63,
122
],
[
122,
23,
283
]
],
[
[
1151,
24,
1339
],
[
1339,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",... | Sunitinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a mino... |
DB00907 | DB01174 | 290 | 697 | [
"DDInter427",
"DDInter1442"
] | Cocaine (topical) | Phenobarbital | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
290,
24,
697
]
],
[
[
290,
63,
362
],
[
362,
1,
697
]
],
[
[
290,
6,
6017
],
[
6017,
45,
697
]
],
[
[
290,
21,
30273
],
[
30273,
... | [
[
[
"Cocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Cocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
Cocaine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is ... |
DB00005 | DB09052 | 1,057 | 250 | [
"DDInter687",
"DDInter220"
] | Etanercept | Blinatumomab | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Major | 2 | [
[
[
1057,
25,
250
]
],
[
[
1057,
24,
949
],
[
949,
63,
250
]
],
[
[
1057,
25,
1362
],
[
1362,
63,
250
]
],
[
[
1057,
25,
305
],
[
305,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (forma... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Etanercept... |
DB00712 | DB08895 | 1,274 | 976 | [
"DDInter763",
"DDInter1825"
] | Flurbiprofen | Tofacitinib | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1274,
24,
976
]
],
[
[
1274,
24,
1017
],
[
1017,
63,
976
]
],
[
[
1274,
63,
723
],
[
723,
24,
976
]
],
[
[
1274,
24,
998
],
[
998,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and A... |
DB00086 | DB00500 | 1,167 | 24 | [
"DDInter1712",
"DDInter1831"
] | Streptokinase | Tolmetin | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Moderate | 1 | [
[
[
1167,
24,
24
]
],
[
[
1167,
24,
886
],
[
886,
1,
24
]
],
[
[
1167,
24,
831
],
[
831,
40,
24
]
],
[
[
1167,
64,
1432
],
[
1432,
2... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
[... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac (Compound) resembles Tolmetin (Compound)
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Tolmetin (Compou... |
DB00207 | DB01069 | 1,570 | 401 | [
"DDInter157",
"DDInter1533"
] | Azithromycin | Promethazine | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1570,
24,
401
]
],
[
[
1570,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1570,
6,
4973
],
[
4973,
45,
401
]
],
[
[
1570,
21,
28709
],
[
28709... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[... | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Azithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Promethazine (Compound)
Azithromycin (Comp... |
DB00682 | DB00973 | 126 | 1,149 | [
"DDInter1951",
"DDInter707"
] | Warfarin | Ezetimibe | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal vill... | Minor | 0 | [
[
[
126,
23,
1149
]
],
[
[
126,
6,
8374
],
[
8374,
45,
1149
]
],
[
[
126,
24,
14
],
[
14,
63,
1149
]
],
[
[
126,
62,
467
],
[
467,
2... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ezetimibe"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ezetimibe (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ezetimibe
Warfarin may cause a... |
DB00372 | DB00776 | 999 | 1,335 | [
"DDInter1793",
"DDInter1360"
] | Thiethylperazine | Oxcarbazepine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
999,
24,
1335
]
],
[
[
999,
24,
1605
],
[
1605,
1,
1335
]
],
[
[
999,
24,
1264
],
[
1264,
63,
1335
]
],
[
[
999,
63,
902
],
[
902,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Oxcarbazepine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction t... |
DB01030 | DB01208 | 869 | 945 | [
"DDInter1835",
"DDInter1705"
] | Topotecan | Sparfloxacin | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Minor | 0 | [
[
[
869,
23,
945
]
],
[
[
869,
62,
739
],
[
739,
1,
945
]
],
[
[
869,
23,
1539
],
[
1539,
1,
945
]
],
[
[
869,
6,
4973
],
[
4973,
45... | [
[
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Topotecan may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Topotecan may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) resembles Sparfloxacin (Compound)
... |
DB00365 | DB01254 | 839 | 1,213 | [
"DDInter842",
"DDInter484"
] | Grepafloxacin | Dasatinib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
839,
25,
1213
]
],
[
[
839,
23,
112
],
[
112,
23,
1213
]
],
[
[
839,
25,
1133
],
[
1133,
24,
1213
]
],
[
[
839,
24,
543
],
[
543,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Grepafloxacin may lead to a major life threatening interaction when taken with Granisetron and Granisetron m... |
DB00514 | DB00962 | 506 | 1,639 | [
"DDInter527",
"DDInter1957"
] | Dextromethorphan | Zaleplon | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Moderate | 1 | [
[
[
506,
24,
1639
]
],
[
[
506,
6,
7524
],
[
7524,
45,
1639
]
],
[
[
506,
7,
17450
],
[
17450,
46,
1639
]
],
[
[
506,
21,
28898
],
[
28898... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (C... | Dextromethorphan (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Zaleplon (Compound)
Dextromethorphan (Compound) upregulates FKBP14 (Gene) and FKBP14 (Gene) is upregulated by Zaleplon (Compound)
Dextromethorphan (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Zalepl... |
DB00903 | DB01276 | 1,680 | 123 | [
"DDInter686",
"DDInter706"
] | Etacrynic acid | Exenatide | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1680,
24,
123
]
],
[
[
1680,
24,
708
],
[
708,
63,
123
]
],
[
[
1680,
63,
1573
],
[
1573,
24,
123
]
],
[
[
1680,
24,
820
],
[
820,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Predniso... |
DB01097 | DB15091 | 1,377 | 676 | [
"DDInter1033",
"DDInter1901"
] | Leflunomide | Upadacitinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1377,
25,
676
]
],
[
[
1377,
23,
1193
],
[
1193,
23,
676
]
],
[
[
1377,
62,
1461
],
[
1461,
23,
676
]
],
[
[
1377,
24,
1430
],
[
1430,... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Leflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc... | Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and V... |
DB00685 | DB09481 | 1,299 | 460 | [
"DDInter1887",
"DDInter1113"
] | Trovafloxacin | Magnesium carbonate | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1299,
24,
460
]
],
[
[
1299,
23,
60
],
[
60,
23,
460
]
],
[
[
1299,
1,
872
],
[
872,
24,
460
]
],
[
[
1299,
24,
853
],
[
853,
24... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
... | Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate int... |
DB00959 | DB11003 | 1,486 | 748 | [
"DDInter1191",
"DDInter100"
] | Methylprednisolone | Anthrax vaccine | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1486,
24,
748
]
],
[
[
1486,
25,
676
],
[
676,
63,
748
]
],
[
[
1486,
24,
1683
],
[
1683,
24,
748
]
],
[
[
1486,
24,
1619
],
[
1619,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
... | Methylprednisolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab... |
DB00688 | DB00781 | 955 | 1,481 | [
"DDInter1251",
"DDInter1489"
] | Mycophenolate mofetil | Polymyxin B | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Moderate | 1 | [
[
[
955,
24,
1481
]
],
[
[
955,
63,
1441
],
[
1441,
40,
1481
]
],
[
[
955,
21,
28719
],
[
28719,
60,
1481
]
],
[
[
955,
63,
91
],
[
91,
... | [
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polymyxin B"
]
],
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baci... | Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin (Compound) resembles Polymyxin B (Compound)
Mycophenolate mofetil (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Polymyxin B (Compound)
Mycophenolate mofetil may caus... |
DB04868 | DB11718 | 478 | 927 | [
"DDInter1293",
"DDInter640"
] | Nilotinib | Encorafenib | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
478,
25,
927
]
],
[
[
478,
62,
112
],
[
112,
23,
927
]
],
[
[
478,
63,
1088
],
[
1088,
24,
927
]
],
[
[
478,
24,
720
],
[
720,
2... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Rifaximin and Rifaxi... |
DB00682 | DB05773 | 126 | 1,047 | [
"DDInter1951",
"DDInter1848"
] | Warfarin | Trastuzumab emtansine | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Major | 2 | [
[
[
126,
25,
1047
]
],
[
[
126,
24,
1091
],
[
1091,
24,
1047
]
],
[
[
126,
25,
848
],
[
848,
24,
1047
]
],
[
[
126,
64,
886
],
[
886,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amp... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Warfarin may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may c... |
DB00557 | DB11901 | 252 | 913 | [
"DDInter895",
"DDInter107"
] | Hydroxyzine | Apalutamide | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
252,
24,
913
]
],
[
[
252,
23,
112
],
[
112,
23,
913
]
],
[
[
252,
63,
600
],
[
600,
24,
913
]
],
[
[
252,
24,
28
],
[
28,
24,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and ... |
DB01069 | DB01105 | 401 | 222 | [
"DDInter1533",
"DDInter1665"
] | Promethazine | Sibutramine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
401,
24,
222
]
],
[
[
401,
21,
28852
],
[
28852,
60,
222
]
],
[
[
401,
64,
839
],
[
839,
23,
222
]
],
[
[
401,
63,
122
],
[
122,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) ... | Promethazine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Sibutramine (Compound)
Promethazine may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Sibutramine... |
DB01611 | DB14881 | 1,487 | 180 | [
"DDInter893",
"DDInter1329"
] | Hydroxychloroquine | Oliceridine | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
1487,
25,
180
]
],
[
[
1487,
63,
112
],
[
112,
23,
180
]
],
[
[
1487,
64,
401
],
[
401,
24,
180
]
],
[
[
1487,
25,
124
],
[
124,
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Hydroxychloroquine may lead to a major life threatening interaction when taken with Promethazine an... |
DB00916 | DB06663 | 112 | 1,154 | [
"DDInter1202",
"DDInter1398"
] | Metronidazole | Pasireotide | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Minor | 0 | [
[
[
112,
23,
1154
]
],
[
[
112,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
112,
23,
1247
],
[
1247,
23,
1154
]
],
[
[
112,
63,
62
],
[
62,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Metronidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side ... | Metronidazole (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effect... |
DB00396 | DB04868 | 989 | 478 | [
"DDInter1529",
"DDInter1293"
] | Progesterone | Nilotinib | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
989,
24,
478
]
],
[
[
989,
6,
6017
],
[
6017,
45,
478
]
],
[
[
989,
7,
7669
],
[
7669,
46,
478
]
],
[
[
989,
6,
1899
],
[
1899,
... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Progesterone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound... | Progesterone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Progesterone (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Nilotinib (Compound)
Progesterone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Nilotinib (Compound)
Progesterone (Compoun... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.